ArticleLiver cancer2023

Phase 2 Study of the PD-1 Inhibitor Serplulimab plus the Bevacizumab Biosimilar HLX04 in Patients with Previously Treated Advanced Hepatocellular Carcinoma.

Zhenggang Ren et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.